Stephanie is currently a Principal Scientist in the Nonclinical Drug Metabolism and Pharmacokinetics group at Boehringer Ingelheim in Ridgefield, Connecticut. Her group focuses on characterizing the metabolism and drug-drug interaction potential of small molecules in the development pipeline using in vitro tools. Stephanie joined Boehringer seven years ago after completing her Ph.D. in Pharmaceutical Sciences at the University of Connecticut School of Pharmacy, where her research efforts involved understanding the impact of postnatal antiepileptic drug exposure on CYP-mediated metabolism and enzyme induction.